LABELS · 39853cd7-bfd1-848f-e063-6294a90a49e4

Testosterone

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-07-09
Captured: 2026-09-09T23:37:44.904352+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SECONDARY EXPOSURE TO TESTOSTERONE Virilization has been reported in children who were secondarily exposed to testosterone gel [see Warnings and Precautions (5.2) and Adverse Reactions (6.2) ] . Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel [see Dosage and Administration (2.2) and Warnings and Precautions (5.2) ] . Healthcare providers should advise patients to strictly adhere to recommended instructions for use [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) and Patient Counseling Information (17) ] . WARNING: SECONDARY EXPOSURE TO TESTOSTERONE See full prescribing information for complete boxed warning Virilization has been reported in children who were secondarily exposed to testosterone gel. ( 5.2 , 6.2 ) Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel. ( 2.2 , 5.2 ) Healthcare providers should advise patients to strictly adhere to recommended instructions for use. ( 2.2 , 5.2 , 17 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE Testosterone gel is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. Limitations of Use: Safety and efficacy of testosterone gel in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. Safety and efficacy of testosterone gel in males less than 18 years old have not been established [see Use in Specific Populations (8.4) ] . Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Dosage and Administration (2) and Clinical Pharmacology (12.3) ] . Testosterone gel is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired). ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired). ( 1 ) Limitations of Use: Safety and efficacy of testosterone gel in men with age-related hypogonadism have not been established ( 1 ) Safety and efficacy of testosterone gel in males less than 18 years old have not been established ( 8.4 ) Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure ( 1 , 12.3 )

Full extracted label fields

application numbers

NDA204399

boxed warning exact

WARNING: SECONDARY EXPOSURE TO TESTOSTERONE Virilization has been reported in children who were secondarily exposed to testosterone gel [see Warnings and Precautions (5.2) and Adverse Reactions (6.2) ] . Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel [see Dosage and Administration (2.2) and Warnings and Precautions (5.2) ] . Healthcare providers should advise patients to strictly adhere to recommended instructions for use [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) and Patient Counseling Information (17) ] . WARNING: SECONDARY EXPOSURE TO TESTOSTERONE See full prescribing information for complete boxed warning Virilization has been reported in children who were secondarily exposed to testosterone gel. ( 5.2 , 6.2 ) Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel. ( 2.2 , 5.2 ) Healthcare providers should advise patients to strictly adhere to recommended instructions for use. ( 2.2 , 5.2 , 17 )

brand names

Testosterone

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a887020f-b41f-49fe-8379-f01147b2a796

generic names

TESTOSTERONE

39853cd7-bfd1-848f-e063-6294a90a49e4

indications and usage exact

1 INDICATIONS AND USAGE Testosterone gel is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. Limitations of Use: Safety and efficacy of testosterone gel in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. Safety and efficacy of testosterone gel in males less than 18 years old have not been established [see Use in Specific Populations (8.4) ] . Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Dosage and Administration (2) and Clinical Pharmacology (12.3) ] . Testosterone gel is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired). ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired). ( 1 ) Limitations of Use: Safety and efficacy of testosterone gel in men with age-related hypogonadism have not been established ( 1 ) Safety and efficacy of testosterone gel in males less than 18 years old have not been established ( 8.4 ) Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure ( 1 , 12.3 )

indications and usage tables exact

is original packager

true

manufacturer names

Upsher-Smith Laboratories, LLC

matched search terms

tumors

package ndcs

0832-1120-65
0832-1120-05
0832-1120-89
0832-1120-35
0832-1121-40
0832-1121-42

product ndcs

0832-1120
0832-1121

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Contraindications ( 4 ) 05/2020

record type

complete_spl_indications_section_candidate

routes

TOPICAL

rxcuis

1596780
1597129

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00200.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA204399

brand names

Testosterone

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 617
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Testosterone gel is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 0

current approval status

not_reconciled

duplicate text group

dup-d4c65045214617f039d6

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-40b1cb86226936f841fd

label id

39853cd7-bfd1-848f-e063-6294a90a49e4

positive predicate support span

end: 53
end exclusive: true
exact text: is indicated
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 41

qualifier mentions

context exact
GE Testosterone gel is indicated for replacement therapy in adult males for conditions associated with a deficiency or absenc
kind
age
polarity
not_inferred
span
end
86
end exclusive
true
exact text
adult
label id
39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start
81
context exact
ndrome, chemotherapy, or toxic damage from alcohol or heavy metals.
kind
biomarker
polarity
not_inferred
span
end
416
end exclusive
true
exact text
metals
label id
39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start
410

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 417
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Testosterone gel is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals.
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239853cd7-bfd1-848f-e063-6294a90a49e4%22

spl effective date

2025-07-09

spl set id

a887020f-b41f-49fe-8379-f01147b2a796

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA204399

brand names

Testosterone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 775
end exclusive: true
exact text: ed): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. The
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 218

current approval status

not_reconciled

duplicate text group

dup-c046d116a7776540960e

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-d8e201c047342b38518b

label id

39853cd7-bfd1-848f-e063-6294a90a49e4

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 575
end exclusive: true
exact text: These men usually have low serum testosterone levels and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 418

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239853cd7-bfd1-848f-e063-6294a90a49e4%22

spl effective date

2025-07-09

spl set id

a887020f-b41f-49fe-8379-f01147b2a796

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA204399

brand names

Testosterone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 971
end exclusive: true
exact text: oxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. Limitations of Use: Safety and efficacy of testosterone gel in men with "age-related hypogonadism" (als
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 376

current approval status

not_reconciled

duplicate text group

dup-7c0ba85d456c07cd1f09

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-391c96dbb2bc033b6982

label id

39853cd7-bfd1-848f-e063-6294a90a49e4

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 771
end exclusive: true
exact text: Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation.
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 576

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239853cd7-bfd1-848f-e063-6294a90a49e4%22

spl effective date

2025-07-09

spl set id

a887020f-b41f-49fe-8379-f01147b2a796

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA204399

brand names

Testosterone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1067
end exclusive: true
exact text: ge. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. Limitations of Use: Safety and efficacy of testosterone gel in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. Safety and efficacy of te
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 572

current approval status

not_reconciled

duplicate text group

dup-6712f9abae9e289447a9

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-78805d038c82d9be4cfc

label id

39853cd7-bfd1-848f-e063-6294a90a49e4

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 867
end exclusive: true
exact text: These men have low testosterone serum levels but have gonadotropins in the normal or low range.
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 772

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239853cd7-bfd1-848f-e063-6294a90a49e4%22

spl effective date

2025-07-09

spl set id

a887020f-b41f-49fe-8379-f01147b2a796

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · limitation of use

application numbers

NDA204399

brand names

Testosterone

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1241
end exclusive: true
exact text: releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. Limitations of Use: Safety and efficacy of testosterone gel in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. Safety and efficacy of testosterone gel in males less than 18 years old have not been established [see Use in Specific Populations (8.4) ] . Topical testosterone products may have different doses, st
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 668

current approval status

not_reconciled

duplicate text group

dup-dd6d15151317bd5cc1a1

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-b5f024f6b632097883c5

label id

39853cd7-bfd1-848f-e063-6294a90a49e4

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1041
end exclusive: true
exact text: Limitations of Use: Safety and efficacy of testosterone gel in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 868

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239853cd7-bfd1-848f-e063-6294a90a49e4%22

spl effective date

2025-07-09

spl set id

a887020f-b41f-49fe-8379-f01147b2a796

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · limitation of use

application numbers

NDA204399

brand names

Testosterone

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1382
end exclusive: true
exact text: the normal or low range. Limitations of Use: Safety and efficacy of testosterone gel in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. Safety and efficacy of testosterone gel in males less than 18 years old have not been established [see Use in Specific Populations (8.4) ] . Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Dosage and Administration (2) and Clinical Pharmacol
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 842

current approval status

not_reconciled

duplicate text group

dup-f275f1800cecd31ae5a9

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-f105f0aea395bc8e2c17

label id

39853cd7-bfd1-848f-e063-6294a90a49e4

positive predicate support span

Source null

qualifier mentions

context exact
Safety and efficacy of testosterone gel in males less than 18 years old have not been established [see Use in Specific Populati
kind
age
polarity
not_inferred
span
end
1109
end exclusive
true
exact text
18 years
label id
39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start
1101

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1182
end exclusive: true
exact text: Safety and efficacy of testosterone gel in males less than 18 years old have not been established [see Use in Specific Populations (8.4) ] .
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 1042

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239853cd7-bfd1-848f-e063-6294a90a49e4%22

spl effective date

2025-07-09

spl set id

a887020f-b41f-49fe-8379-f01147b2a796

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 7 · risk or warning

application numbers

NDA204399

brand names

Testosterone

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 1596
end exclusive: true
exact text: o as "late-onset hypogonadism") have not been established. Safety and efficacy of testosterone gel in males less than 18 years old have not been established [see Use in Specific Populations (8.4) ] . Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Dosage and Administration (2) and Clinical Pharmacology (12.3) ] . Testosterone gel is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congen
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 983

current approval status

not_reconciled

duplicate text group

dup-9f60910e980287f7c954

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-e2acd8b1e2a6128839f9

label id

39853cd7-bfd1-848f-e063-6294a90a49e4

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1396
end exclusive: true
exact text: Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Dosage and Administration (2) and Clinical Pharmacology (12.3) ] .
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 1183

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239853cd7-bfd1-848f-e063-6294a90a49e4%22

spl effective date

2025-07-09

spl set id

a887020f-b41f-49fe-8379-f01147b2a796

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 8 · positive indication candidate

application numbers

NDA204399

brand names

Testosterone

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1814
end exclusive: true
exact text: terone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Dosage and Administration (2) and Clinical Pharmacology (12.3) ] . Testosterone gel is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired). ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired). ( 1 ) Limitations of Use: Safety and efficacy of testosterone gel in men with age-related hypogonadism have not been established ( 1 ) Sa
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 1197

current approval status

not_reconciled

duplicate text group

dup-82e3ecce211a1c0bad84

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-3ea4646dccf8ae40286d

label id

39853cd7-bfd1-848f-e063-6294a90a49e4

positive predicate support span

end: 1438
end exclusive: true
exact text: is an androgen indicated
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 1414

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1614
end exclusive: true
exact text: Testosterone gel is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired).
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 1397

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239853cd7-bfd1-848f-e063-6294a90a49e4%22

spl effective date

2025-07-09

spl set id

a887020f-b41f-49fe-8379-f01147b2a796

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 9 · unclassified context

application numbers

NDA204399

brand names

Testosterone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1876
end exclusive: true
exact text: s an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired). ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired). ( 1 ) Limitations of Use: Safety and efficacy of testosterone gel in men with age-related hypogonadism have not been established ( 1 ) Safety and efficacy of testosterone gel in males less than 18 ye
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 1415

current approval status

not_reconciled

duplicate text group

dup-a442c1327b9f748fef72

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-94b21bc47ac99c8a427a

label id

39853cd7-bfd1-848f-e063-6294a90a49e4

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1676
end exclusive: true
exact text: ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired).
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 1615

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239853cd7-bfd1-848f-e063-6294a90a49e4%22

spl effective date

2025-07-09

spl set id

a887020f-b41f-49fe-8379-f01147b2a796

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · limitation of use

application numbers

NDA204399

brand names

Testosterone

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 2072
end exclusive: true
exact text: n males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired). ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired). ( 1 ) Limitations of Use: Safety and efficacy of testosterone gel in men with age-related hypogonadism have not been established ( 1 ) Safety and efficacy of testosterone gel in males less than 18 years old have not been established ( 8.4 ) Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure ( 1 , 12.3 )
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 1477

current approval status

not_reconciled

duplicate text group

dup-8e28a177d00dfb0c90ac

extraction review status

automated_candidate_pending_source_review

generic names

TESTOSTERONE

ind-span-96f2070ff155d8acacac

label id

39853cd7-bfd1-848f-e063-6294a90a49e4

positive predicate support span

Source null

qualifier mentions

context exact
Safety and efficacy of testosterone gel in males less than 18 years old have not been established ( 8.4 ) Topical testosterone
kind
age
polarity
not_inferred
span
end
1879
end exclusive
true
exact text
18 years
label id
39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start
1871

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 2072
end exclusive: true
exact text: ( 1 ) Limitations of Use: Safety and efficacy of testosterone gel in men with age-related hypogonadism have not been established ( 1 ) Safety and efficacy of testosterone gel in males less than 18 years old have not been established ( 8.4 ) Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure ( 1 , 12.3 )
label id: 39853cd7-bfd1-848f-e063-6294a90a49e4
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 5cc103538f0c2c9c9009cb5590389c48347d8324eff52b1ea443bca15280a1e0
start: 1677

source url

https://api.fda.gov/drug/label.json?search=id%3A%2239853cd7-bfd1-848f-e063-6294a90a49e4%22

spl effective date

2025-07-09

spl set id

a887020f-b41f-49fe-8379-f01147b2a796

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice